Latest 5 articles from heartwire
- Air pollutants mediate effects on heart health through inflammation and thrombosis
May 17, 2012 17:15 EDT - Statins benefit those at much lower CV risk
May 16, 2012 18:30 EDT - Azithromycin may up chance of sudden cardiac death
May 16, 2012 17:00 EDT - So long, Plavix, what a ride! Clopidogrel patent expires
May 16, 2012 14:45 EDT - COMFORTABLE-AMI: Bioerodable polymer DES trumps bare metal in STEMI
May 16, 2012 10:50 EDT
RAPTOR: Femoral to radial access for PCI
Posted Nov 15, 2009
at 07:50 AM, EDT
by Seth Bilazarian
Presented here at the Scientific Sessions, the RAPTOR trial provided more reasons to convert from femoral to radial access for PCI. In an evolving healthcare reimbursement environment there may be an added push toward the radial approach. Have you been planning to make the transition to radial access or have you been holding back?
See:
Experienced operators can switch easily and rapidly to radial access PCI: RAPTOR
Bailout no more: Transradial PCI goes mainstream, but the US lags behind
Cardiac catheterization access sites: An international perspective
Two new studies support radial-access PCI over the femoral approach
Previous posts
Choosing wisely for interventionalists: Seth Bilazarian's top 5
1 Comments |
Posted May 10, 2012
at 03:15 AM, EDT by Seth
at 03:15 AM, EDT by Seth
The Choosing Wisely initiative: The ACC and ASNC list what NOT to do
No comments |
Posted May 02, 2012
at 10:25 AM, EDT by Seth
at 10:25 AM, EDT by Seth
Left ventriculography: Setting the record straight
2 Comments |
Posted Apr 11, 2012
at 03:35 AM, EDT by Seth
at 03:35 AM, EDT by Seth
Facebook, LinkedIn, and YouTube: What place in the cardiology practice?
No comments |
Posted Apr 04, 2012
at 04:00 PM, EDT by Seth
at 04:00 PM, EDT by Seth
Renal-nerve denervation to combat resistant hypertension
5 Comments |
Posted Mar 26, 2012
at 05:25 PM, EDT by Seth
at 05:25 PM, EDT by Seth
Also from theheart.org
About Dr Seth Bilazarian
Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.
Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.
Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.
Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
About this blog
My intent is to create a forum for dialogue on issues pertinent to private practice cardiology around topics such as:
- Integration of new data and guidelines on inpatient and outpatient practice in clinical and interventional cardiology
- Practice approaches to the extra clinical issues in dealing with managed care insurers
- Strategies for navigating the restrictions of pharmacy benefits managers (PBMs) on pharmacologic therapies for our patients
- Experiences with restrictions on testing and imaging














Comments